Runnymede Capital Advisors Inc. Makes New Investment in Boston Scientific Corporation $BSX

Runnymede Capital Advisors Inc. purchased a new position in Boston Scientific Corporation (NYSE:BSX) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 9,719 shares of the medical equipment provider’s stock, valued at approximately $927,000.

Other hedge funds have also bought and sold shares of the company. Steph & Co. purchased a new stake in Boston Scientific in the 3rd quarter worth $25,000. Financial Consulate Inc. purchased a new stake in Boston Scientific in the 3rd quarter worth $25,000. Murphy & Mullick Capital Management Corp lifted its stake in Boston Scientific by 200.0% in the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 170 shares in the last quarter. FWL Investment Management LLC purchased a new stake in Boston Scientific in the 2nd quarter worth $26,000. Finally, United Community Bank lifted its stake in Boston Scientific by 115.7% in the 3rd quarter. United Community Bank now owns 274 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 147 shares in the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have commented on BSX. UBS Group decreased their price target on shares of Boston Scientific from $120.00 to $105.00 and set a “buy” rating on the stock in a research note on Tuesday, March 17th. Jefferies Financial Group restated a “buy” rating on shares of Boston Scientific in a report on Monday, March 16th. National Bank Financial set a $115.00 target price on shares of Boston Scientific in a report on Monday, February 2nd. Truist Financial reduced their target price on shares of Boston Scientific from $95.00 to $92.00 and set a “buy” rating on the stock in a report on Wednesday, March 18th. Finally, Barclays reduced their target price on shares of Boston Scientific from $136.00 to $124.00 and set an “overweight” rating on the stock in a report on Tuesday, February 3rd. One research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $104.05.

Insider Buying and Selling

In related news, CEO Michael F. Mahoney sold 160,901 shares of the company’s stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the transaction, the chief executive officer directly owned 1,411,735 shares in the company, valued at approximately $131,983,105.15. This represents a 10.23% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.50% of the company’s stock.

Key Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Leerink reiterated an “Outperform” after the CHAMPION‑AF readout met primary safety and efficacy endpoints, reinforcing the clinical story for BSX’s cardiac franchise and supporting buy‑side interest. Leerink Reiterates Outperform
• Positive Sentiment: Citigroup trimmed its price target (from $94 to $87) but kept a “Buy” rating, signaling continued analyst conviction that shares have upside despite recent share weakness. Citigroup Lowers PT
• Neutral Sentiment: Erste Group marginally cut FY2026 EPS (from $3.46 to $3.45) — a tiny revision that doesn’t materially change the consensus outlook but reflects modest near‑term estimate trimming. Erste Group Lowers Estimate
• Neutral Sentiment: An investor group is probing the proposed acquisition of Penumbra (the deal would pay cash or BSX shares). That scrutiny could slow or complicate deal completion and introduces execution risk if shareholder litigation or regulatory questions arise. Penumbra Sale Probe
• Negative Sentiment: Multiple law firms have filed or circulated investor alerts and class‑action notices accusing BSX and certain officers of securities violations for the period July 23, 2025–Feb 3, 2026; deadlines to seek lead‑plaintiff status are being publicized (notably May 4, 2026). The wave of litigation notices (Bragar Eagel & Squire, Robbins Geller, Bronstein Gewirtz & Grossman, Faruqi & Faruqi, Pomerantz, Rosen, Bernstein Liebhard, Gross, etc.) increases litigation risk, potential defense costs and headline volatility. Bragar Alert Robbins Geller Bronstein Faruqi

Boston Scientific Stock Performance

Boston Scientific stock opened at $62.69 on Thursday. The company has a market cap of $93.17 billion, a PE ratio of 32.31, a price-to-earnings-growth ratio of 0.97 and a beta of 0.78. Boston Scientific Corporation has a twelve month low of $60.90 and a twelve month high of $109.50. The company’s 50-day moving average price is $72.73 and its 200-day moving average price is $88.57. The company has a quick ratio of 1.08, a current ratio of 1.62 and a debt-to-equity ratio of 0.46.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 EPS for the quarter, beating the consensus estimate of $0.78 by $0.02. The company had revenue of $5.29 billion for the quarter, compared to the consensus estimate of $5.29 billion. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The firm’s revenue was up 15.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.70 EPS. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. On average, equities research analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.